PROGRAMS & GROUPS

PLEASE CLICK ON THE CORRESPONDING PROGRAMS BELOW

VHIO's Cancer Genomics, Molecular Oncology, Proteomics, and Translational Genomics Groups led by Ana Vivancos, Paolo Nuciforo, Francesc Canals, and Aleix Prat respectively, are responsible for the development of VHIO's cutting-edge core technologies and platforms. These groups also pursue, implement, and develop their own independent research lines and projects.

CORE TECHNOLOGIES GROUPS

PLEASE CLICK ON THE CORRESPONDING GROUPS BELOW

CANCER GENOMICS
Imagen
Ana Vivancos
Principal Investigator
MOLECULAR ONCOLOGY
Imagen
Paolo Nuciforo
Principal Investigator
PROTEOMICS
Imagen
Francesc Canals
Principal Investigator
TRANSLATIONAL GENOMICS
Imagen
Aleix Prat
Principal Investigator

Cancer Genomics Group / Ana Vivancos

Imagen

Principal Investigator
Ana Vivancos

Specialized Technicians
Ginevra Caratù
Deborah G. Lo Giacco
Judit Matito
Leire Mendizábal
Zighereda Ogbah

Bioinformatician
Francesco M. Mancuso

Bioinformatics Technical Auxiliary
Laura Muiños

Summary / Cancer Genomics Group

VHIO’s Cancer Genomics Group serves as a Core Technology laboratory. Our activities bridge the preclinical and clinical fields of cancer research. We provide cutting-edge applications in cancer genomics through the use of state-of-the-art technologies and also develop novel fully validated tests that are used in the clinical research setting (Pre-screening Program).

Our lab is equipped with a genotyping platform (MassARRAY, Sequenom), an n-Counter (Nanostring) platform and two NextGen Sequencers; MiSeq and HiSeq2500, Illumina.

Our research activities focus on developing novel multiplexed tests that are optimized to FFPE-derived nucleic acids. Once developed, our tests are validated and used in clinical research – VHIO’s Prescreening Program. We have developed and routinely implemented an Amplicon-seq approach to sequence >60 genes (Illumina), as well as a gene fusion panel (with the capacity of detecting over 100 recurrent gene fusions) based on nCounter technology.

VHIO’s Pre-screening Program is nucleated around the activity of two VHIO groups - our Cancer Genomics Group and Molecular Oncology led by Ana Vivancos and Paulo Nuciforo respectively, and is dedicated to performing molecular profiling in over 1500 patients per year that are candidates for enrollment in Phase I clinical trials carried out at our Research Unit for Molecular Therapy of Cancer (UITM) – “la Caixa”. Patients’ suitability for inclusion in a given clinical trial is decided upon based on their respective genomic or pathologic profile. As a reflection of our dedication to excellence and quality in the services we provide, we have undergone ISO 15189 accreditation for our main testing methods.

We are also involved in a number of translational research projects including the identification of mechanisms of resistance to targeted therapies, study of clonal populations, as well as defining novel therapeutic opportunities based on mutation profiles, in collaboration with both preclinical and clinical researchers at VHIO, working on solid tumors.

Strategic Goals / Cancer Genomics Group

  1. Develop and implement improved strategies for routine patient pre-screening in a high quality setting (ISO 15189 accreditation).
  2. Provide cutting-edge applications in cancer genomics through the use of novel technologies and protocol development.

Highlights 2015 / Cancer Genomics Group

  1. Validation and implementation of an Ampliconseq VHIO-Card panel (NGS) to allow mutation detection in over 60 genes. Validation and implementation of a Gene Fusion panel based on nCounter technology.
  2. VHIO is one of the six founding partners of the Cancer Core Europe Consortium alongside the Gustave Roussy Cancer Campus Grand Paris (Villejuif, France), Cambridge Cancer Centre (Cambridge, UK), Karolinska Institute (Stockholm, Sweden), Netherlands Cancer Institute – NKI (Amsterdam, The Netherlands), and the National Center for Tumor Diseases – DKFZ-NCT (Heidelberg, Germany). Our group is appointed co-leader of the Consortium’s Genomics Taskforce and is responsible for the alignment of genomic testing across all 6 institutions.
  3. Implementation of liquid biopsy in routine clinical practice. We have incorporated a Digital-PCR platform, BEAMing, for the detection of RAS mutations in first-line metastatic colorectal cancer.

PI Paper Pick / Cancer Genomics Group

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560-562.

Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase Inhibition Blocks Wnt/b-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016;22(3):644-656. Epub 2015 Jul 29.

García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin Cancer Res. 2015;21(24):5499-5510.

Horizons 2016 / Cancer Genomics Group

  1. Obtain ISO15189 accreditation for our VHIO-Card Amplicon-seq panel (NGS). We received an International Standarization Organization ISO 15189:2007 accreditation for our MassARRAY platform. This is in accordance with our commitment to generating high quality results for our patients. We are undergoing an accreditation process for our Amplicon-seq panel.
  2. Increase ctDNA profiling. We plan to expand ctDNA profiling to other applications and tumor types, specifically by the use of ddPCR.
  3. Establish routine CNA detection in patient FFPE samples. Copy number alterations (CNA) are a well-known mechanism driving tumorogenesis, resistance to treatments, etc. There are a number of molecules in the clinical setting that target proteins coded by genes that suffer copy number gains or losses in the genome, such as EGFR, ERBB2, MET , and RB1. We plan to develop and implement an approach that will allow us to routinely profile these events in FFPE samples. In combination with our Mutation and Gene Fusion Cards, we will be able to provide a comprehensive profile of patient samples.

Publications / Cancer Genomics Group

  1. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Nat Commun. 2015 Nov 10;6:8839. doi: 10.1038/ncomms9839. PMID: 26554728.
  2. García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin Cancer Res. 2015 Aug 13. [Epub ahead of print]
  3. Arques O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernandez N, Caratu G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espin E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase inhibition blocks Wnt/β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. Clin Cancer Res. 2015 Jul 29. pii: clincanres.3081.2014. [Epub ahead of print]
  4. Ferrándiz-Pulido C, Hernández-Losa J, Masferrer E, Vivancos A, Somoza R, Marés R, Valverde C, Salvador C, Placer J, Morote J, Pujol RM, Ramon y Cajal S, de Torres I, Toll A, García-Patos V. Identification of somatic gene mutations in penile squamous cell carcinoma. Genes Chromosomes Cancer. 2015 Oct;54(10):629-37.
  5. Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015 Jun;21(6):560-2.
  6. Lluch-Senar M, Delgado J, Chen WH, Lloréns-Rico V, O'Reilly FJ, Wodke JA, Unal EB, Yus E, Martínez S, Nichols RJ, Ferrar T, Vivancos A, Schmeisky A, Stülke J, van Noort V, Gavin AC, Bork P, Serrano L. Defining a minimal cell: essentiality of small ORFs and ncRNAs in a genome-reduced bacterium. Mol Syst Biol. 2015;11(1):780.

Projects / Cancer Genomics Group

  1. Inhibidores de la Ruta Wnt/Beta-Catenin como prometedora terapia para el tratamiento del cáncer de pulmón.

Molecular Oncology Group / Paolo Nuciforo

Imagen

Principal Investigator
Paolo Nuciforo

Attending Physicians
Claudia Aura
Roberta Fasani
Mª Alejandra Gabaldón
Ludmila Prudkin

Laboratory Supervisor
Jose Jiménez

Laboratory Assistant
Mª Ángeles Díaz

Technicians
Mª del Carmen Díaz
Francisca Gallego
Paola Martínez
Gertrudis Sánchez
César Sevillano

Administration
Mª Alejandra Iglesias

Summary / Molecular Oncology Group

The Molecular Oncology Group’s mission is to apply state-of-the-art tissue-based technologies to basic, translational, and clinical research with a clear focus on developing and validating novel tumor biomarkers for precision cancer medicine. The group is one of VHIO’s Core Technology Platforms and is therefore central to VHIO’s research activities. We actively participate in all research projects involving the use of human tissue collected from patients, including biomarker analyses for patient stratification, tissue banking, the development of primary xenograft models, and circulating tumor cells (CTC) analyses.

Core Facility activities in 2015:

We provided support to more than 180 clinical trials conducted at Vall d’Hebron, representing more tan 60% of all trials open at our institution. Our clinical trials activities range from the coordination of simple collection, storage and shipment, developing and running multiple assays for real-time patient inclusion, as well as pharmacodynamic monitoring and dose finding.

During this year, we have performed over 3000 molecular determinations on samples for patient inclusion in clinical trials and over 14,000 tests to support basic and translation research programs. We have also been the central laboratory for 2 national and 6 international studies.

In 2015, our laboratory successfully maintained and expanded the catalogue of molecular tests run under the prestigious ISO15189 quality accreditation.

Research activities in 2015:

We published two papers addressing the role of PI3K pathway activation as a mechanism of resistance in HER2-positive breast cancer (Nuciforo et al, Annals of Oncology 2015; Majewski et al, Journal of Clinical Oncology 2015).

In addition, we established and strengthened several key collaborations with pharmaceutical companies to carry out translational studies focused on the identification of predictive biomarkers of response to FGFR inhibitors, the definition of target populations for two antibody-drug conjugates projects and HER family proteins quantification in breast cancer using Selected Reaction Monitoring Mass Spectrometry (SRM-MS).

The latter study, conducted in collaboration with MGH and OncoplexDx/Nantomics, aimed to demonstrate the feasibility of using SRM-MS in clinical samples and highlighted the relevance of quantitative target measurement in predicting response to targeted therapies (Nuciforo et al, Breast Cancer Research 2015; Scaltriti et al, Clinical Cancer Research 2015).

Additional projects included a study exploring the prevalence of MET copy number variation, MET expression and MET related genomic alterations in solid tumors.

Strategic Goals / Molecular Oncology Group

  1. Discovery and validation of novel biomarkers using tissue-based technologies.
  2. Serve as a core facility for VHIO research programs.
  3. Act as a central and local laboratory in clinical trials.
  4. Apply molecular pathology strategies to support early clinical drug development programs.
  5. Define molecular targets epidemiology to improve personalized treatment strategies.

PI Paper Pick / Molecular Oncology Group

Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, Cortes J, Scaltriti M. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol Oncol. 2016;10(1):138-147. Epub 2015 Sep 15.

Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol. 2015;1(4):448-454. Erratum in: JAMA Oncol. 2015;1(8):1172.

Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Quantification of HER family receptors in breast cancer. Breast Cancer Res. 2015;17:53.

Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Peña L, Ellis C, Eidtmann H, Piccart-Gebhart MJ, Scaltriti M, Baselga J. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Ann Oncol. 2015;26(7):1494-1500.

Highlights 2015 / Molecular Oncology Group

  1. Supported over 180 clinical trials for simple management and analyses. Central laboratory in different national and international studies.
  2. Over 3000 molecular determinations on samples for patient inclusion into clinical trials and over 14,000 tests performed for basic and translation research programs.
  3. Development of biomarker strategies for FGFR, MET, and Antibody-drug conjugates early clinical development programs.
  4. Validation of the predictive value of protein quantification using SRM-MS.
  5. Maintenance and expansion of tests under the ISO15189 accreditation.

Horizons 2016 / Molecular Oncology Group

  1. Maintain and expand the number of ISO15189-accredited diagnostic tests to be used for patient selection and targeted therapies.
  2. Develop and validate new technologies for biomarker analyses in FFPE tissues, especially focusing in target quantification.
  3. Continue to explore the value of protein biomarkers quantification in improving personalized medicine treatment decision.
  4. Improve processes related to clinical trial sample coordination and internal prescreening program.

Publications / Molecular Oncology Group

  1. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L. Oncotarget. 2015 Nov 10;6(35):37269-80. doi: 10.18632/oncotarget.5495.
  2. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, Cortes J, Scaltriti M. Mol Oncol. 2016 Jan;10(1):138-47. doi: 10.1016/j.molonc.2015.09.002. Epub 2015 Sep 15.
  3. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. Clin Cancer Res. 2015 Dec 15;21(24):5499-510. doi: 10.1158/1078-0432.CCR-14-3091. Epub 2015 Aug 13.
  4. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizán EM, Horvath Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, Rivas G, Pazos A, Gozalbes R, Palmer HG, Hurlstone A, Crespo P. Cancer Cell. 2015 Aug 10;28(2):170-82. doi: 10.1016/j.ccell.2015.07.001.
  5. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081. Epub 2015 Jul 29.
  6. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Mod Pathol. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24.
  7. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. JAMA Oncol. 2015 Jul;1(4):448-54. doi: 10.1001/jamaoncol.2015.0830. Erratum in: JAMA Oncol. 2015 Jul;1(4):544. JAMA Oncol. 2015 Nov;1(8):1172.
  8. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Prat A, Galván P, Jimenez B, Buckingham W, Jeiranian HA, Schaper C, Vidal M, Álvarez M, Díaz S, Ellis C, Nuciforo P, Ferree S, Ribelles N, Adamo B, Ramón Y Cajal S, Peg V, Alba E. Clin Cancer Res. 2016 Feb 1;22(3):560-6. doi: 10.1158/1078-0432.CCR-15-0630. Epub 2015 Jul 7.
  9. Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortés J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J. PLoS One. 2015 Jun 15;10(6):e0129876. doi: 10.1371/journal.pone.0129876. eCollection 2015.
  10. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration. Ann Oncol. 2015 Jul;26(7):1280-91. doi: 10.1093/annonc/mdv161. Epub 2015 May 27. Review.
  11. Quantification of HER family receptors in breast cancer. Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Breast Cancer Res. 2015 Apr 9;17:53. doi: 10.1186/s13058-015-0561-8. Review.
  12. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Peña L, Ellis C, Eidtmann H, Piccart-Gebhart MJ, Scaltriti M, Baselga J. Ann Oncol. 2015 Jul;26(7):1494-500. doi: 10.1093/annonc/mdv175. Epub 2015 Apr 7.
  13. Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Palmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortés J. Sci Rep. 2015 Feb 11;5:8179. doi: 10.1038/srep08179. No abstract available.
  14. PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Stern HM, Gardner H, Burzykowski T, Elatre W, O'Brien C, Lackner MR, Pestano GA, Santiago A, Villalobos I, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Nuciforo P, Bee V, Mackey J, Slamon DJ, Press MF. Clin Cancer Res. 2015 May 1;21(9):2065-74. doi: 10.1158/1078-0432.CCR-14-2993. Epub 2015 Feb 3.
  15. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de la Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J. J Clin Oncol. 2015 Apr 20;33(12):1334-9. doi: 10.1200/JCO.2014.55.2158. Epub 2015 Jan 5.
  16. 16 High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart M, Baselga J. Clin Cancer Res. 2015 Feb 1;21(3):569-76. doi: 10.1158/1078-0432.CCR-14-1824. Epub 2014 Dec 2.

Projects / Molecular Oncology Group

  1. Identification and validation of pharmacodynamic biomarkers related to the development of a new multityrosine kinase inhibitor and analysis of clinical samples obtained from the PhI clinical trial.
  2. Prevalence of MET copy number variation, MET expression and MET related genomic alterations in all solid tumors pre-screening program.
    WINTHER. A Phase II study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in Subjects with Advanced Solid Tumors.
  3. Antibody-drugs conjugates biomarkers development: determination of CEACAM5 and LAMP-1 expression in primary and metastatic colorectal cancer.
  1. Analysis of FGFR1, FGFR2 and FGFR3 Gene Copy Number and Protein Expression Level in Tumor Tissue Samples coming from Patient Derived Xenografts.
  2. Quantitative measurement of HER2 levels by multiplexed mass spectrometry from FFPE tissue in patients treated with anti-HER2 based therapy.

Proteomics Group / Francesc Canals

Imagen

Principal Investigator
Francesc Canals

Post-Doctoral Fellows
Núria Colomé
Laura Villarreal

Technicians
Luna Martin
Anna Sabé

Summary / Proteomics Group

Proteomics is directed to the characterization of the entire set of proteins - proteome -expressed by a particular cell or tissue under specific physiological or pathological conditions. The application of proteomic technologies to cancer research is a rapidly expanding field - not only for basic research but also for the discovery of diagnostic or disease-progression biomarkers.

We mainly focus on the application of proteomic techniques to the identification and characterization of substrates of metalloproteases involved in tumor progression. Metalloproteases of the ADAM and ADAMTS families are known to play a crucial role in the regulation of the tumor microenvironment by mediating the remodeling of the extracelular matrix and the cleavage of specific extracellular and membrane proteins. Knowledge surrounding the substrates of these proteases in the context of tumor cells is required in order to elucidate their role in tumor growth and metastasis as well as evaluate their potential use as therapeutic targets. Our group employs mass spectrometry-based proteomic strategies to search for new substrates of these proteases and analyze their involvement in tumor progression.

Our research also adopts proteomic techniques for the screening and validation of biomarkers for cancer diagnostics, personalized therapy and the tracking of disease. Our group’s focus has mainly centered on the establishment of a TGF beta activity-related protein signature, to be used for patient stratification and monitoring of glioma.

Our laboratory is a member of the Spanish Consortium Chromosome 16 HPP which forms part of the HUPO Human Proteome Project. This multicenter, international project aims to develop an entire map of the proteins encoded by the human genome following a chromosome-centric strategy to advance our understanding of human biology in health and disease. Focusing on important aspects of biology, this project is set to impact on ongoing disease-oriented research.

As a Core Facility, we also provide state-of-the-art proteomic methodologies to VHIO researchers as well as implement new developments within the field in order to provide the very latest proteomic strategies and technologies.

Strategic Goals / Proteomics Group

  1. Provide services in proteomic techniques to other research groups as a core facility.
  2. Explore the role of ADAM and ADAMTS metalloproteases in cancer through proteomic analysis.
  3. Proteomic screening for new biomarkers to help develop cancer therapeutics.
  4. Contribute to mapping the Chromosome 16 proteome as part of the Human Proteome Project.

Highlights 2015 / Proteomics Group

  1. The provision of proteomic services to VHIO groups, oncoprofessionals at the Vall d’Hebron.
  2. University Hospital (HUVH), and members of the ProteoRed-Instituto Salud Carlos III network.
  3. Work in progress towards the validation of a biomarker signature to facilitate patient selection and the monitoring of TGFbeta inhibitor-based treatment of glioma.
  4. Participation in the Spanish Consortium Chromosome 16 HPP (part of the HUPO Human Proteome Project).

PI Paper Pick / Proteomics Group

Aguilera Ó, González-Sancho JM, Zazo S, Rincón R, Fernández AF, Tapia O, Canals F, Morte B, Calvanese V, Orgaz JL, Niell N, Aguilar S, Freije JM, Graña O, Pisano DG, Borrero A, Martínez-Useros J, Jiménez B, Fraga MF, García-Foncillas J, López-Otín C, Lafarga M, Rojo F, Muñoz A. Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer. Oncotarget. 2015;6(8):5903-5917.

Iñaki Alvarez, Javier A. Collado, Roger Colobran, Montserrat Carrascal, M. Teresa Ciudad, Francesc Canals, Eddie A. James, William W. Kwok, Martina Gärtner, Bruno Kyewski, Ricardo Pujol-Borrell, Dolores Jaraquemada. Central T cell tolerance: Identification of tissue-restricted autoantigens in the thymus HLA-DR peptidome. J Autoimmun. 2015;60:12-19.

Vilà-Rico Marta, Colomé-Calls Núria, Martín-Castel Luna, Gay Marina, Azorín Sebastián, Vilaseca Marta, Planas Antoni, Canals Francesc. Quantitative analysis of post-translational modifications in human serum transthyretin associated with familial amyloidotic polyneuropathy by targeted LC-MS and intact protein MS. J Proteomics. 2015;127(Pt B):234-246.

Andrew J. Percy, Jessica Tamura-Wells, Juan Pablo Albar, Jesus M. Arizmendi, Francisco J. Blanco, Francesc Canals, Fernando Corrales, Gilberto Domont, Guadalupe Espadas, Concha Gill, Mark Molloy, Young-Ki Paik, Mark Raftery, Lekha Sleno, Justina C. Wolters, Jong Shin Yoo, Victor Zgoda, Carol E. Parker, and Christoph H. Borchers. Inter-laboratory Evaluation of Instrument Platforms and Workflows for Quantitative Accuracy and Reproducibility. EuPA Open Proteomics. 2015;8:6-15.

Horizons 2016 / Proteomics Group

  1. Explore the potential of ADAM and ADAMTS metalloproteases shedding products as biomarkers for breast tumor management.
  2. Develop Immuno-MS assays to monitor a TGBbeta activity biomarker signature for glioma therapeutics.
  3. Continued involvement in the HUPO Human Proteome Project, through the Spanish Chromosome 16 HPP Consortium.
  4. Continue to provide services in state-of-the art proteomic methodologies to other research groups.

Publications / Proteomics Group

  1. Aguilera Ó, González-Sancho JM, Zazo S, Rincón R, Fernández AF, Tapia O, Canals F, Morte B, Calvanese V, Orgaz JL, Niell N, Aguilar S, Freije JM, Graña O, Pisano DG, Borrero A, Martínez-Useros J, Jiménez B, Fraga MF, García-Foncillas J, López-Otín C, Lafarga M, Rojo F, Muñoz A. (2015); Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer. Oncotarget. Mar 20;6(8):5903-17.
  2. Iñaki Alvarez, Javier A. Collado, Roger Colobran, Montserrat Carrascal, M. Teresa Ciudad, Francesc Canals, Eddie A. James, William W. Kwok, Martina Gärtner, Bruno Kyewski, Ricardo Pujol-Borrell, Dolores Jaraquemada. (2015); Central T cell tolerance: Identification of tissue-restricted autoantigens in the thymus HLA-DR peptidome. Journal of Autoimmunity. Jun;60:12-9.
  3. Tababat-Khani P, de la Torre C, Canals F, Bennet H, Simo R, Hernandez C, Fex M, Agardh CD, Hansson O, Agardh E. (2015); Photocoagulation of human retinal pigment epithelium in vitro: unravelling the effects on ARPE-19 by transcriptomics and proteomics. Acta Ophthalmol. Jun;93(4):348-54.
  4. Rosa M, Bech-Serra JJ, Canals F, Zajac JM, Talmont F, Arsequell G, Valencia G. (2015); Optimized Proteomic Mass Spectrometry Characterization of Recombinant Human μ-Opioid Receptor Functionally Expressed in Pichia pastoris Cell Lines. J Proteome Res. Aug 7;14(8):3162-73.
  5. Vilà-Rico Marta, Colomé-Calls Núria, Martín-Castel Luna, Gay Marina, Azorín Sebastián, Vilaseca Marta, Planas Antoni, Canals Francesc. (2015); Quantitative analysis of post-translational modifications in human serum transthyretin associated with familial amyloidotic polyneuropathy by targeted LC-MS and intact protein MS. Journal of Proteomics. Sep 8;127(Pt B):234-46.
  6. Alex Campos, Ramón Díaz, Salvador Martínez-Bartolomé, Jose Sierra, Oscar Gallardo, Eduard Sabidó, Maria López-Lucendo, J. Ignacio Casal, Carla Pasquarello, Alexander Scherl, Cristina Chiva, Eva Borras, Antonia Odena, Félix Elortza, Mikel Azkargorta, Nieves Ibarrola, Francesc Canals, Juan P. Albar, Eliandre Oliveira. (2015); Multicenter Experiment for Quality Control of Peptide-Centric LC-MS/MS Analysis – A Longitudinal Performance Assessment. Journal of Proteomics. Sep 8;127(Pt B):264-74.
  7. Andrew J. Percy, Jessica Tamura-Wells, Juan Pablo Albar, Jesus M. Arizmendi, Francisco J. Blanco, Francesc Canals, Fernando Corrales, Gilberto Domont, Guadalupe Espadas, Concha Gill, Mark Molloy, Young-Ki Paik, Mark Raftery, Lekha Sleno, Justina C. Wolters, Jong Shin Yoo, Victor Zgoda, Carol E. Parker, and Christoph H. Borchers. (2015); Inter-laboratory Evaluation of Instrument Platforms and Workflows for Quantitative Accuracy and Reproducibility. EuPA Open Proteomics. Sep, 8,6-15.
  8. Ferrer-Mayorga G, Alvarez-Díaz S, Valle N, De Las Rivas J, Mendes M, Barderas R, Canals F, Tapia O, Casal JI, Lafarga M, Muñoz A. (2015); Cystatin D locates in the nucleus at sites of active transcription and modulates gene and protein expression. J Biol Chem. Oct 30;290(44):26533-48.

Projects / Proteomics Group

  1. Proteómica cuantitativa en el marco del Proyecto Proteoma Humano para la búsqueda y validación de biomarcadores en cáncer
    Funding Agency: Instituto de Salud Carlos III Ref. PI13/01703
    Duration: 01/01/2014 - 31/12/2016
  1. Plataforma de Recursos Biomoleculares y Bioinformáticos (PRB2)
    Funding Agency: Instituto de Salud Carlos III (ISCIII) Ref. PT13/0001
    Duration: 01/01/2014 - 31/12/2017

Translational Genomics Group / Aleix Prat

Imagen

Principal Investigator
Aleix Prat

Clinical Research Technician
Patricia Galván

Specialist Physician in Breast Cancer (Collaboration)
María Jesús Vidal Losada

Technician
Débora Martínez

Summary / Translational Genomics Group

2015 has been another highly productive year for VHIO’s Translational Genomics Group. On the one hand, we have been the first in Europe to successfully implement a clinically applicable gene expression-based test, known as PAM50, in two prospective clinical trials in patients with metastatic breast cancer. In addition, we have analyzed >1.000 samples and have continued to provide scientific guidance and advice to several collaborators both at VHIO and overseas, leading to multiple publications in high-impact factor journals. Moreover, my lab has expanded its participation in the retrospective genomic analyses of tumor samples from several national and international clinical trials (e.g. PAMELA, GEICAM2012-09, NeoEribulin, EGF30008, EGF104900, LPT109096, CIBOMA/2004-01/GEICAM 2003-11 and CHER-LOB).

Our group has also led important advances regarding the clinical implications of breast cancer heterogeneity. In a first article, published in Clinical Cancer Research, we were the first to validate the PAM50 assay in core biopsies from primary and metastatic tumors and evidence that this approach can help predict response to chemotherapy. In a second paper, published in BMC Medicine, in one of the largest datasets reported to date with more than 900 patients with breast cancer, we showed that PAM50 intrinsic subtyping predicts response and survival following multiagent chemotherapy. These findings have led to the clinical implementation at our hospital of the PAM50 assay at diagnosis before any therapeutic strategy is established for breast cancer patients.

Finally, we have collaborated with several renowned investigators. In one study, published in Science Translational Medicine, we showed that during PI3K inhibition in patients with luminal breast cancer, the tumor becomes more estrogen-dependent (i.e. more Luminal A). These findings have led, in part, to the development of these agents in combination with endocrine therapy. In a second study, we identified a gene, called MAF, as being potentially responsible for the development of breast cancer bone metastasis.

Our group has participated in 15 articles providing scientific advice and/or performing gene expression analyses including 13 original research articles and 1 review article: 3 as first author, 1 as second, and 2 as last author. For 2015 our group’s Impact Factor totaled at 110.5 (average of 8 per publication).

Strategic Goals / Translational Genomics Group

  1. Use genomic data to guide clinical trial design and biomarker development in order to identify more optimal treatment regimens for cancer patients.
  2. Use gene expression data to better characterize different tumor types and better understand cancer biology.
  3. Help implement gene expression-based tests in the clinical setting.

Highlights 2015 / Translational Genomics Group

  1. Implementation of the PAM50/PROSIGNA® nCounter-based assay in the clinical setting.
  2. Identification and molecular characterization of the intrinsic molecular subtypes of breast cancer within HER2+ breast cancer.
  3. Susan G. Komen Career Catalyst Grant to identify patients with HER2+ breast cancer that do not need chemotherapy.
  4. Fund for National Healthcare Research (FIS) grant to study triple-negative breast cancer.
  5. Participation in correlative science studies across ∼10 clinical trials.

PI Paper Picker / Translational Genomics Group

Prat A, Galván P, Jimenez B, Buckingham W, Jeiranian HA, Schaper C, Vidal M, Álvarez M, Díaz S, Ellis C, Nuciforo P, Ferree S, Ribelles N, Adamo B, Ramón Y Cajal S, Peg V, Alba E. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Clin Cancer Res. 2016;22(3):560-566. Epub 2015 Jul 7.

Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, Viladot M, Pineda E, Arance A, Muñoz M, Paré L, Cheang MC, Adamo B, Perou CM. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med. 2015;13:303.

Vidal M, Peg V, Galván P, Tres A, Cortés J, Ramón y Cajal S, Rubio IT, Prat A. Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast. Mol Oncol. 2015;9(6):1081-1090.

Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A, Muñoz M. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24 Suppl 2:S26-S35.

Horizons 2016 / Translational Genomics Group

  1. Perform gene expression analyses in the NEOERIBULIN clinical trial.
  2. Lead the PAMELA clinical study and the correlative scientific part.
  3. Continue to help implement the PROSIGNA® subtype predictor in the clinical setting.
  4. Complete gene expression analyses in the GEICAM/2003-06 clinical trial.
  5. Implement a molecular screening program at VHIO.
  6. Molecularly characterize other tumor types beyond breast cancer.
  7. Continue and expand worldwide collaborations for biomarker development.

Publications / Translational Genomics Group

  1. Sun Z, Prat A, Cheang MC, Gelber RD, Perou CM. Chemotherapy Benefit for "ER-Positive" Breast Cancer and Contamination of Non-Luminal Subtypes - Waiting for TAILORx and RxPONDER. Ann Oncol. 2015 Jan;26(1):70-4. doi: 10.1093/annonc /mdu493.
  2. Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, Malik F, Paulson AK, D'Angelo RC, Korkaya S, Baker TL, Esen ES, Prat A, Liu S, Kleer CG, Thomas DG, Wicha MS, Korkaya H. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene. 2015 Feb 5;34(6):671-80. doi: 10.1038/onc.2014.4.
  3. Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. RE: How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, or More? Response. J Natl Cancer Inst. 2015 Feb 24;107(4). pii: djv029. doi: 10.1093/jnci/djv029.
  4. Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med. 2015Apr15;7(283):283ra51.doi: 10.1126/scitranslmed.aaa4442.
  5. Cheang MC, Martin M, Nielsen TO1, Prat A, Voduc D1, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E,Carrasco E, Caballero R, Tu D, Pritchard KI, Levine MN, Bramwell VH, Parker J, Bernard PS, Ellis MJ, Perou CM, Di Leo A, Carey LA. Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologisti>. 2015 May;20(5):474-82. doi:10.1634/theoncologist.2014-0372.
  6. Vidal, M; Peg, V; Galván, P; Cortés, J; Ramón y Cajal, S; Rubio, I; Prat, A. Gene Expression-based Classifications of Fibroadenomas and Phyllodes tumours of the Breast. Mol Oncol. 2015 Jun;9(6):1081-90. doi: 10.1016/j.molonc.2015.01.003.
  7. Martín M; González-Rivera M; Morales S; de la Haba-Rodriguez J; González-Cortijo L; Manso L; Albanell J; González-Martín A; González S; Arcusa A; de la Cruz-Merino L; Rojo F; Vidal M; Galván P; Aguirre E; Morales C; Ferree S; Pompilio K; Casas M; Caballero R; Goicoechea U; Carrasco E; Michalopoulos S; Hornberger J; Prat A. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. Curr Med Res Opin. 2015 Jun;31(6):1129-37. doi: 10.1185/03007995.2015.1037730.
  8. Prat A; Galván P; Jimenez B; Buckingham W; Jeiranian HA; Schaper C; Vidal M; Álvarez M; Díaz S; Ellis C; Nuciforo P; Ferree S; Ribelles N; Adamo B; Ramón y Cajal S; Peg V and Alba E. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Clin Cancer Res. 2015 Jul 7. pii: clincanres.0630.2015. doi: 10.1158/1078-0432.CCR-15-0630.
  9. Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A, Muñoz M. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015 Nov;24 Suppl 2:S26-35. doi: 10.1016/j.breast.2015.07.008. Epub 2015 Aug 5.
  10. Arques O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernandez N, Caratu G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espin E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase inhibition blocks Wnt/β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. Clin Cancer Res. 2015 Jul 29. pii: clincanres.3081.2014. doi: 10.1158/1078-0432.CCR-14-3081.
  11. Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E. Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. Oncotarget. 2015 Sep 29;6(29):28173-82. doi: 10.18632/oncotarget.4405.
  12. Pavlovic M*, Arnal-Estape A*, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albeniz X, Morales M, Urosevic J, Gawrzak S, Rovira A, Prat A, Nonell L, Lluch A, Jean-Mairet J, Coleman R, Albanell J, Gomis JR. *Authors contributed equally to this work. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. JNCI J Natl Cancer Inst (2015) 107 (12): djv256 doi: 10.1093/jnci/djv256.
  13. Font C, Fernández-Avilés F, Calderon C, García-Fernández T, Arab N, Pineda E, Buxó E4, Ayora P, Carreño M, Pereira V, Viladot M, Moreno C, Gallego C, Hernando A, Creus N, Barrera C, Alcaraz R, Sanchez J, Prat A, Tuca A. Home management of acute medical complications in cancer patients:a prospective pilot study. Support Care Cancer 2015 Nov 10. [Epub ahead of print].
  14. Gendoo DM, Ratanasirigulchai N, Schröder MS, Paré L, Parker JS, Prat A, Haibe-Kains B. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics. 2015 Nov 24. pii: btv693. [Epub ahead of print].
  15. Aleix Prat, Cheng Fan, Aranzazu Fernández, Katherine A. Hoadley, Rossella Martinello, Maria Vidal, Margarita Viladot, Estela Pineda, Ana Arance, Montserrat Muñoz, Laia Paré, Maggie C. U. Cheang, Barbara Adamo and Charles M. Perou. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med. 2015 Dec 18;13(1):303. doi: 10.1186/s12916-015-0540-z.

Awards and Recognition 2015 / Translational Genomics Group

  1. Susan G. Komen Career Catalyst Grant. Title: HER2-enriched intrinsic molecular subtype as a predictor of response to dual HER2 blockade.
  2. Programa Estatal de Fomento de la Investigación Científica y Tecnológica. Proyectos de investigación en salud. Title: Validación de un predictor genómico en cáncer de mama triple-negativo.
  3. 2015 Extraordinary Doctorate Award (2013).Universitat Autònoma de Barcelona. UAB.

Invited Lectures 2015 / Translational Genomics Group

  1. 01/15 Master in Biomedicine. Breast Cancer. “Molecular subtypes”. University of Barcelona, Barcelona, España.
  2. 01/15 Foro de Actualización en Cáncer de Mama. “Nuevos tipos intrínsecos en cáncer de mama: aportaciones presentes y futuras de la nueva clasificación”. Madrid, España.
  3. 01/15 The Annual Meeting of the Israeli Society for Clinical Oncology and Radiation Therapy. “Clinical implications of the intrinsic molecular subtypes of breast cancer”. Israeli Society for Clinical Oncology and Radiation Therapy (ISCORT) Eilat, Israel.
  4. 04/15 VIII Curso Biología y Patología moleculares para médicos. Hospital Clínic de Barcelona. España.
  5. 04/15 I Simposio Nacional Genómica Aplicada en Oncología. Spanish National Cancer Research Centre (CNIO). “¿Qué nos ofrece Nanostring (Prosigna) en el día a día? Mi experiencia”. CNIO. Madrid, España.
  6. 05/15 Simposio Internacional de Oncología Traslacional. “Breast cancer genetics: new findings, new classifications”. Fundació UAB. Barcelona, España.
  7. 05/15 VII Simposium Bases Biológicas del Cáncer y Terapias personalizadas. “Cáncer de mama y subtipos intrínsecos. Pasado, presente y future”. Centro de Investigación del Cáncer de Salamanca. Salamanca, España.
  8. 05/15 2015 ASCO Annual Meeting. “Predicting Response in Triple-Negative and HER2-Positive Breast Cancer: Unlocking Pieces to Solve the Puzzles”. McCormick Place, Chicago, IL, USA.
  9. 06/15 Therapeutic and Clinical implications of the genomic landscape of breast cancer workshop. “Therapeutic and Clinical Implications of the genomic landscape of breast cancer”. University Campus Bio-Medico of Rome. Rome, Italia.
  10. 06/15 Jornada Firmas Genéticas Cáncer de mama. “Prosigna”. Hospital Universitario Quiron-Dexeus. Barcelona, España.
  11. 06/15 XVI Diploma en Patología Mamaria – Senología. Errores a evitar en el diagnóstico de certeza en senología. “¿El diagnóstico molecular aporta más información?” Facultad de Medicina Universidad de Barcelona – UB. Barcelona, España.
  12. 06/15 8º Revisión Anual GEICAM de Avances en Cáncer de Mama (RAGMA15) “Avances en modelos preclínicos y biología”. GEICAM. Madrid, España.
  13. 06/15 Milan Breast Cancer Conference–Webcast and Ressidential. “When to prescribe gene signature testing (as opposed to relying upon immunohistochemistry)?” European Institute of Oncology. Milan, Italia.
  14. 07/15 Seminario In-House IDIBAPS. “Overcoming treatment resistance in luminal breast cancer”. Esteve Auditorium IDIBAPS-CEK Building. Barcelona, España.
  15. 09/15 11th Meet The Professor Advanced International Breast Cancer Course (AIBCC) “Clinical validity versus clinical utility of genomic tests”. Accademia Nazionale di Medicina. Padua. Italia.
  16. 10/15 Meeting "EMIT Project". “Clinical implications of intrinsic breast cancer subtypes”. Inst for Cancer Research. Oslo University Hospital. Oslo. Noruega.
  17. 10/15 XV ASEICA International Congress. “Clinical implications of intrinsic breast cancer subtypes”. Sevilla. España.
  18. 10/15 2º Congreso Español de la MAMA. “Implicaciones clínicas presentes y futuras de la biología intrínseca de cáncer de mama”. SESPM. Madrid, España.
  19. 10/15 Keynote COMBATing, Breast Cancer 2015. “Current and Future Clinical Implications of the Intrinsic Subtypes of Breast Cancer”. Düsseldorf, Alemania.
  20. 10/15 XV Congreso SEOM. “Ayudas a la decisión terapéutica en tumores luminales”. Madrid, España.
  21. 10/15 Medical Director’s Meeting at Celgene. “Clinical implications of the breast cancer intrinsic subtypes: present and future”. Barcelona, España.
  22. 11/15 Seminario en el Servicio de Radioterapia del Hospital Clinic de Barcelona. “Clinical implications of the intrinsic molecular subtypes of breast cancer”. Barcelona, España.
  23. 11/15 SOLTI Scientific Meeting: Targeting Breast Cancer in 2015 Inside and Out: from the Cell Cycle to the tumor microenvironment. Promising agents and strategies in the race for personalized breast cancer therapy. “Keynote lecture: promising agents and strategies in the race for personalized breast cancer therapy”. Madrid, España.
  24. 12/15 Master Oficial Universitario en Medicina Translacional. “Molecular classification of breast cancer Facultad de Medicina, Universidad de Barcelona – UB, Barcelona, España.